On 2 September the FDA approved a supplemental application to Pfizer's new drug application for abrocitinib (Cibinqo), the oral JAK1 inhibitor licensed for moderate-to-severe atopic dermatitis.
The FDA record does not say what the supplement changed. Supplements cover anything from labelling and manufacturing to dosing or population changes, and most are administrative. Until the updated label is published, prescribing should not change on the strength of this record.
The boxed warning on JAK inhibitors — serious infection, major adverse cardiovascular events, malignancy and thrombosis — continues to apply. Abrocitinib's regulatory status in India is not established by this record.
- Check the updated FDA label before assuming any change to indication or dose.
- Keep baseline and monitoring bloods as per the current label.
- Continue to screen for cardiovascular and thrombotic risk before starting a JAK inhibitor.
- Do not tell patients about a new indication on the basis of this approval.
Why it matters
A supplement can quietly change a label, and prescribers are the ones expected to notice.
Don't overread it
A licence supplement is not a new indication; the record gives no clinical detail.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free